The Adenosinergic Pathway in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Immune checkpoint inhibitors (ICIs) targeting PD-(L)1 and CTLA-4 have transformed non-small cell lung cancer (NSCLC) treatment.
• However, only a subset of patients experiences long-term benefits, highlighting the need to understand and overcome ICI resistance.
• The tumor microenvironment (TME) significantly influences immune responses and ICI efficacy.

Purpose of the Study:

• To review the role of the adenosinergic pathway and extracellular adenosine (eADO) in the TME of NSCLC.
• To explore novel immune checkpoints and mechanisms of ICI resistance.
• To summarize preclinical and clinical data on targeting the adenosinergic pathway for improved ICI response in NSCLC.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of the adenosinergic pathway and adenosine's impact within the TME.
• Focus on molecules targeting the adenosinergic pathway for NSCLC treatment.

Main Results:

• The adenosinergic pathway, particularly extracellular adenosine (eADO), is a key modulator of the immune response within the TME.
• Dysregulation of adenosine signaling can contribute to resistance against current ICIs in NSCLC.
• Emerging data suggests that targeting the adenosinergic pathway holds potential for enhancing ICI efficacy.

Conclusions:

• The adenosinergic pathway represents a promising therapeutic target to overcome ICI resistance in NSCLC.
• Modulating eADO levels within the TME could improve clinical outcomes for NSCLC patients treated with ICIs.
• Further research into adenosinergic pathway inhibitors is warranted to optimize NSCLC immunotherapy.